常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.28/-1.35
|
|
企业价值
8.23M
|
| 资产负债 |
|
每股账面净值
0.47
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
893.99K
|
|
每股收益
0.15
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/08 12:18 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing. |

1.31 
